AT1‐AA Is Produced in Offspring in Response to Placental Ischemia and Is Lowered by B‐Cell Depletion Without Compromising Overall Offspring Health

Background Preeclampsia, new‐onset hypertension during pregnancy alongside other organ dysfunction, is the leading cause of mortality for the mother and low birth weight for the baby. Low birth weight contributes to high risk of cardiovascular disorders later in life. Women with preeclampsia have ac...

Full description

Saved in:
Bibliographic Details
Main Authors: Nathan Campbell, Evangeline Deer, Dylan Solise, Denise C. Cornelius, Ty Turner, Lorena M. Amaral, Owen Herrock, Ariel Jordan, Shivani Shukla, Tarek Ibrahim, Babbette LaMarca
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.031417
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850150079563825152
author Nathan Campbell
Evangeline Deer
Dylan Solise
Denise C. Cornelius
Ty Turner
Lorena M. Amaral
Owen Herrock
Ariel Jordan
Shivani Shukla
Tarek Ibrahim
Babbette LaMarca
author_facet Nathan Campbell
Evangeline Deer
Dylan Solise
Denise C. Cornelius
Ty Turner
Lorena M. Amaral
Owen Herrock
Ariel Jordan
Shivani Shukla
Tarek Ibrahim
Babbette LaMarca
author_sort Nathan Campbell
collection DOAJ
description Background Preeclampsia, new‐onset hypertension during pregnancy alongside other organ dysfunction, is the leading cause of mortality for the mother and low birth weight for the baby. Low birth weight contributes to high risk of cardiovascular disorders later in life. Women with preeclampsia have activated B cells producing agonistic autoantibodies to AT1‐AA (angiotensin II type I receptor). We hypothesize that rituximab, a B cell‐depleting chemotherapeutic, will deplete maternal B cells in reduced uterine perfusion pressure (RUPP) rats without worsening the effect of placental ischemia on pup growth and survival. Methods and Results To test this hypothesis, the RUPP procedure was performed, and rituximab was continuously infused via miniosmotic pump. Maternal blood and tissues were collected. A separate group of dams were allowed to deliver, pup weights were recorded, and at 4 months of age, tissues were collected from offspring. Immune cells were measured via flow cytometry, and AT1‐AA was quantified using a contraction bioassay. Blood pressure increased in RUPP rats and was normalized with rituximab treatment. RUPP offspring also had increased circulating B cells, cytolytic natural killer cells, and increased circulating AT1‐AA, which were normalized with maternal rituximab treatment. This is the first study to analyze the AT1‐AA in RUPP offspring, which was normalized with rituximab. Conclusions Our findings indicate that perinatal rituximab lowers maternal mean arterial pressure in RUPP rats and improves birth weight, circulating AT1‐AA, and circulating natural killer cells, indicating that rituximab improves adverse fetal outcomes in response to placental ischemia.
format Article
id doaj-art-bc9482f48b3540708e4f48b304e77a8e
institution OA Journals
issn 2047-9980
language English
publishDate 2024-02-01
publisher Wiley
record_format Article
series Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
spelling doaj-art-bc9482f48b3540708e4f48b304e77a8e2025-08-20T02:26:40ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802024-02-0113410.1161/JAHA.123.031417AT1‐AA Is Produced in Offspring in Response to Placental Ischemia and Is Lowered by B‐Cell Depletion Without Compromising Overall Offspring HealthNathan Campbell0Evangeline Deer1Dylan Solise2Denise C. Cornelius3Ty Turner4Lorena M. Amaral5Owen Herrock6Ariel Jordan7Shivani Shukla8Tarek Ibrahim9Babbette LaMarca10Department of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSDepartment of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSDepartment of Obstetrics and Gynecology University of Mississippi Medical Center Jackson MSDepartment of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSDepartment of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSDepartment of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSDepartment of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSDepartment of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSDepartment of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSDepartment of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSDepartment of Pharmacology & Toxicology University of Mississippi Medical Center Jackson MSBackground Preeclampsia, new‐onset hypertension during pregnancy alongside other organ dysfunction, is the leading cause of mortality for the mother and low birth weight for the baby. Low birth weight contributes to high risk of cardiovascular disorders later in life. Women with preeclampsia have activated B cells producing agonistic autoantibodies to AT1‐AA (angiotensin II type I receptor). We hypothesize that rituximab, a B cell‐depleting chemotherapeutic, will deplete maternal B cells in reduced uterine perfusion pressure (RUPP) rats without worsening the effect of placental ischemia on pup growth and survival. Methods and Results To test this hypothesis, the RUPP procedure was performed, and rituximab was continuously infused via miniosmotic pump. Maternal blood and tissues were collected. A separate group of dams were allowed to deliver, pup weights were recorded, and at 4 months of age, tissues were collected from offspring. Immune cells were measured via flow cytometry, and AT1‐AA was quantified using a contraction bioassay. Blood pressure increased in RUPP rats and was normalized with rituximab treatment. RUPP offspring also had increased circulating B cells, cytolytic natural killer cells, and increased circulating AT1‐AA, which were normalized with maternal rituximab treatment. This is the first study to analyze the AT1‐AA in RUPP offspring, which was normalized with rituximab. Conclusions Our findings indicate that perinatal rituximab lowers maternal mean arterial pressure in RUPP rats and improves birth weight, circulating AT1‐AA, and circulating natural killer cells, indicating that rituximab improves adverse fetal outcomes in response to placental ischemia.https://www.ahajournals.org/doi/10.1161/JAHA.123.031417autoantibodiesimmunologyoffspringpreeclampsia
spellingShingle Nathan Campbell
Evangeline Deer
Dylan Solise
Denise C. Cornelius
Ty Turner
Lorena M. Amaral
Owen Herrock
Ariel Jordan
Shivani Shukla
Tarek Ibrahim
Babbette LaMarca
AT1‐AA Is Produced in Offspring in Response to Placental Ischemia and Is Lowered by B‐Cell Depletion Without Compromising Overall Offspring Health
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
autoantibodies
immunology
offspring
preeclampsia
title AT1‐AA Is Produced in Offspring in Response to Placental Ischemia and Is Lowered by B‐Cell Depletion Without Compromising Overall Offspring Health
title_full AT1‐AA Is Produced in Offspring in Response to Placental Ischemia and Is Lowered by B‐Cell Depletion Without Compromising Overall Offspring Health
title_fullStr AT1‐AA Is Produced in Offspring in Response to Placental Ischemia and Is Lowered by B‐Cell Depletion Without Compromising Overall Offspring Health
title_full_unstemmed AT1‐AA Is Produced in Offspring in Response to Placental Ischemia and Is Lowered by B‐Cell Depletion Without Compromising Overall Offspring Health
title_short AT1‐AA Is Produced in Offspring in Response to Placental Ischemia and Is Lowered by B‐Cell Depletion Without Compromising Overall Offspring Health
title_sort at1 aa is produced in offspring in response to placental ischemia and is lowered by b cell depletion without compromising overall offspring health
topic autoantibodies
immunology
offspring
preeclampsia
url https://www.ahajournals.org/doi/10.1161/JAHA.123.031417
work_keys_str_mv AT nathancampbell at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT evangelinedeer at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT dylansolise at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT deniseccornelius at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT tyturner at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT lorenamamaral at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT owenherrock at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT arieljordan at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT shivanishukla at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT tarekibrahim at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth
AT babbettelamarca at1aaisproducedinoffspringinresponsetoplacentalischemiaandisloweredbybcelldepletionwithoutcompromisingoveralloffspringhealth